fruquintinib
hutchmed
[]
day #3 #gi23 #crc and anal #cancer updates! come visit our #qol data from phase 3 trial #fresco2 of #fruquinitinb vs. placebo #abs 67 (d4) today (pending fda review for new possible option for our patients)! 
Co-Director/Co-Leader GI Oncology Research; Director, Young Adult Cancers Program; Co-Chair, NCI GI Steering Committee; and Director for Strategic Relations